Argent Biopharma Limited (RGT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 06/30
(Values in thousands)
| 06-2025 | 06-2024 | 06-2023 | 06-2022 | 06-2021 | |
| Sales | 583 | 891 | 3,388 | 4,732 | 2,963 |
| Cost of Goods | 137 | 687 | 1,937 | 2,922 | 1,652 |
| Gross Profit | 446 | 204 | 1,451 | 1,810 | 1,310 |
| Operating Expenses | 15,889 | 18,466 | 17,049 | 16,071 | 13,380 |
| Operating Income | -15,443 | -18,262 | -15,598 | -14,261 | -12,070 |
| Interest Expense | 51 | 482 | 337 | 190 | 369 |
| Other Income | -2,350 | 1,196 | -5,196 | -2,687 | -1,093 |
| Pre-tax Income | -17,844 | -17,548 | -21,132 | -17,139 | -13,532 |
| Income Tax | 0 | 0 | 2 | 0 | -27 |
| Net Income Continuous | -17,844 | -17,548 | -21,134 | -17,139 | -13,504 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -463 |
| Minority Interests | N/A | 18 | 310 | 373 | 2 |
| Net Income | $-17,844 | $-17,531 | $-20,824 | $-16,766 | $-13,965 |
| EPS Basic Total Ops | N/A | -0.47 | -7.10 | -7.90 | -8.30 |
| EPS Basic Continuous Ops | N/A | -0.47 | -7.10 | -7.90 | -8.10 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | 0.00 | 0.00 | -0.20 |
| EPS Diluted Total Ops | N/A | -0.47 | -7.10 | -7.90 | -8.30 |
| EPS Diluted Continuous Ops | N/A | -0.47 | -7.10 | -7.90 | -8.10 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | 0.00 | 0.00 | -0.24 |
| EBITDA(a) | $-17,004 | $-15,772 | $-20,043 | $-16,701 | $-12,671 |